Neurodegenerative Disease TreatmentMarket Drivers:-
Major driver for growth of theglobal NeurodegenerativeDisease Treatment Market is robust pipeline of drugs. For instance,FlorbetapirF 18 sponsored by Avid Radiopharmaceuticals, a pharmaceuticalcompany focused on improving clinical development of drugs completed phase 2clinical trials in 2017. This drug is used as biomarkers for neurodegenerativediseases such as Alzheimer’s disease. F 18 T807 sponsored by Washington schoolof medicine is in phase 2 clinical trials since 2015. This drug is used totreat Amyotrophic Lateral Sclerosis (ALS).
Mergers and acquisitions bymarket players are expected to drive the neurodegenerative disease treatmentmarket growth. For instance, in June 2018, Alexion Pharmaceuticals Inc.,US-based global biopharmaceutical company merged with Complement Pharma,Netherlands-based biotech company to develop preclinical C-6 complementinhibitor CP010 for neurodegenerative disorders such as Parkinson’s disease andAmyotrophic Lateral Sclerosis (ALS). C6 inhibition prevents the formation ofMembrane attack complex (MAC), a complex of terminal complement proteins, whichhas potential to treat a variety of central nervous system disorders.
Launch of new drugs and highprevalence of neurodegenerative diseases are expected to support the growth inneurodegenerative disease treatment market size. For instance, in 2018, ArunABiomedical launched exosome (Cell derived vesicles that are present in blood)biologic to treat Central Nervous System (CNS) and neurodegenerative diseases.Exosome biologics are used in treatment of CNS and neurodegenerative diseasessuch as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic LateralSclerosis (ALS).
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1860
Neurodegenerative diseasesinvolves progressive loss of function and structure of neurons, which sometimesalso includes death of neurons. Major cause of neurodegeneration is depositionof toxic protein substance in the brain, which hinders the function ofmitochondria in the brain. Some of the neurodegenerative diseases are caused bygenetic mutations due to expansion of CAG trinucleotide and poly Q tract, forinstance, Huntington’s disease and spinocerebellar ataxias. Someneurodegenerative diseases are caused due to aggregation of misfolded proteins,for instance Alzheimer’s disease, Huntington disease, and Parkinson’s disease.One of the common factors for cell death in neurodegeneration is intrinsicmitochondrial apoptotic pathway, for instance Amyotrophic lateral sclerosis.Alzheimer’s disease is caused due to aggregation of misfolded protein.Parkinson’s disease affects the central nervous system by abnormal accumulationof protein alpha-synuclein bound to ubiquitin in the damaged cells.Huntington’s disease is a genetic disorder that causes breakdown of nerve cellsin the brain.
Increasing research forneurodegenerative diseases treatment is expected to boost growth ofneurodegenerative disease treatment market. For instance, E-Scape Bio, abiopharmaceutical company, would be investing more than US$ 63 million onresearch for treatment of Parkinson’s and Alzheimer’s disease from 2017 fordevelopment for new drug.
Lack of reimbursement policiesprovided by the government and hospitals for the treatment of neurodegenerativediseases such as Alzheimer’s disease, Parkinson’s disease, and AmyotrophicLateral Sclerosis (ALS) are restraining growth of the market.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/neurodegenerative-disease-treatment-market-1860
Neurodegenerative DiseaseTreatment Market Regional Analysis:-
North America is expected to holddominant position in global neurodegenerative disease treatment market due tothe strategic mergers and acquisitions among key players. For instance, in2018, Abbvie Inc. a biopharmaceutical company merged with Voyager Therapeutics,a gene therapy developing company to develop gene therapies to treatAlzheimer’s disease. In 2014, Bristol Myers Squibb, an American pharmaceuticalcompany acquired iPierian Inc. a drug discovery platform that developstherapies for neurodegenerative diseases. Bristol Myers Squibb acquirediPierian’s leading drug IPN007. IPN007 is a monoclonal antibody to treatprogressive supranuclear palsy (a medical condition in which consists ofdeterioration of cells in various areas of brain that control thinking and bodymovement).
Europe neurodegenerative diseasetreatment market is expected to witness a significant growth due to increasingprevalence of neurodegenerative diseases. According to a survey conducted byParkinson Association of the Carolinas in 2016, more than 60000 new people inthe U.S. are diagnosed with Parkinson’s disease annually. Therefore, increasingnumber of neurodegenerative disorders is in turn driving growth of theneurodegenerative disease treatment market.
Neurodegenerative DiseaseTreatment Market Key Players:-
Key players operating in globalneurodegenerative disease treatment market include Novartis AG, Pfizer Inc.,Merck Serono, Biogen Inc., Teva Pharmaceutical Industries Ltd., UCB, C.H.Boehringer Sohn AG & Co. KG, Sanofi S.A., GlaxoSmithKline, and Neuro-HitechInc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1860
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
